Araştırma Makalesi
BibTex RIS Kaynak Göster

Yıl 2021, Cilt: 5 Sayı: 6, 620 - 622, 01.06.2021

Recep Demirci Okan Akyüz

https://doi.org/10.28982/josam.807627

Öz

Kaynakça

  • 1. Gnudi L, Coward RJ, Long DA. Diabetic nephropathy: perspective on novel molecular mechanisms. Trends Endocrinol Metab. 2016;27(11):820-30. doi: 10.1016/j.tem.2016.07.002.
  • 2. Gross JL, De Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes care. 2005;28(1):164-76. doi: 10.2337/diacare.28.1.164.
  • 3. de Zeeuw D, Remuzzi G, Parving HH, et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation. 2004;110(8):921-7. doi: 10.1161/01.CIR.0000139860.33974.28.
  • 4. Macisaac RJ, Jerums G. Diabetic kidney disease with and without albuminuria. Curr Opin Nephrol Hypertens. 2011;20(3):246-57. doi: 10.1097/MNH.0b013e3283456546.
  • 5. Valmadrid CT, Klein R, Moss SE, Klein BE. The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch Intern Med. 2000;160(8):1093-100. doi: 10.1001/archinte.160.8.1093.
  • 6. Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med. 2008;148(1):30-48. doi: 10.7326/0003-4819-148-1-200801010-00190.
  • 7. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851-60. doi: 10.1056/NEJMoa011303.
  • 8. Fernandez-Fernandez B, Ortiz A, Gomez-Guerrero C, Egido J. Therapeutic approaches to diabetic nephropathy—beyond the RAS. Nat Rev Nephrol. 2014;10(6):325. doi: 10.1038/nrneph.2014.74.
  • 9. Gallagher H, Suckling RJ. Diabetic nephropathy: where are we on the journey from pathophysiology to treatment? Diabetes Obes Metab. 2016 Jul;18(7):641-7. doi: 10.1111/dom.12630.
  • 10. Gündüz F, Kuru O, Sentürk UK. Effect of nitric oxide on exercise-induced proteinuria in rats. J Appl Physiol (1985). 2003 Nov;95(5):1867-72. doi: 10.1152/japplphysiol.00599.2003.
  • 11. Roccatello D, Mengozzi G, Ferro M et al. Isosorbide 5 mononitrate administration increases nitric oxide blood levels and reduces proteinuria in IgA glomerulonephritis patients with abnormal urinary endothelin/cyclic GMP ratio. Clin Nephrol. 1995;44(3):163-9.
  • 12. Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007 May;39(2):175-91. doi: 10.3758/bf03193146.
  • 13. Lin J, Knight EL, Hogan ML, Singh AK. A comparison of prediction equations for estimating glomerular filtration rate in adults without kidney disease. J Am Soc Nephrol. 2003 Oct;14(10):2573-80. doi: 10.1097/01.asn.0000088721.98173.4b.
  • 14. Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care. 2005;28(1):164-76. doi: 10.2337/diacare.28.1.164.
  • 15. Akhan O, Ardahanli I. Hypoglycemia in the emergency, is there any effect on endothelial and diastolic functions? Echocardiography. 2021 Mar;38(3):450-459. doi: 10.1111/echo.14988.
  • 16. Kim MK. Treatment of diabetic kidney disease: current and future targets. Korean J Intern Med. 2017 Jul;32(4):622-630. doi: 10.3904/kjim.2016.219.

The effect of isosorbide-mononitrate on proteinuria in patients with diabetic nephropathy

Yıl 2021, Cilt: 5 Sayı: 6, 620 - 622, 01.06.2021

Recep Demirci Okan Akyüz

https://doi.org/10.28982/josam.807627

Öz

Background/Aim: Diabetic nephropathy (DN) occurs in approximately 40% of patients with Type 1 and Type 2 diabetes mellitus (DM) and is one of the most common causes of end-stage renal disease (ESRD). New treatment strategies are needed to prevent DN. This study aims to investigate the effect of the use of isosorbide-mononitrate (IMN) on diabetic nephropathy.
Methods: In this study, patients with type 2 diabetes mellitus were divided into two groups, as those using and not using IMN to evaluate whether IMN reduces proteinuria. Biochemical parameters and proteinuria values were recorded and comparatively analyzed.
Results: The urea and creatinine values of patients with type 2 DM who were using IMN were significantly higher and e-GFR values were significantly lower than those of the control group (P=0.049, P=0.001, P=0.013, respectively). However, the proteinuria amounts of Type 2 DM patients using IMN (0.98 g/day [0.52-1.43]) were significantly lower than those who were not (1.61 g/day [1.02-2.69] (P=0.001)).
Conclusion: The addition of nitrate to angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB) in the treatment of patients with DN may be a new alternative for reducing proteinuria.

Anahtar Kelimeler

Diabetic nephropathy Isosorbide-mononitrate Proteinuria

Kaynakça

  • 1. Gnudi L, Coward RJ, Long DA. Diabetic nephropathy: perspective on novel molecular mechanisms. Trends Endocrinol Metab. 2016;27(11):820-30. doi: 10.1016/j.tem.2016.07.002.
  • 2. Gross JL, De Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes care. 2005;28(1):164-76. doi: 10.2337/diacare.28.1.164.
  • 3. de Zeeuw D, Remuzzi G, Parving HH, et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation. 2004;110(8):921-7. doi: 10.1161/01.CIR.0000139860.33974.28.
  • 4. Macisaac RJ, Jerums G. Diabetic kidney disease with and without albuminuria. Curr Opin Nephrol Hypertens. 2011;20(3):246-57. doi: 10.1097/MNH.0b013e3283456546.
  • 5. Valmadrid CT, Klein R, Moss SE, Klein BE. The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch Intern Med. 2000;160(8):1093-100. doi: 10.1001/archinte.160.8.1093.
  • 6. Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med. 2008;148(1):30-48. doi: 10.7326/0003-4819-148-1-200801010-00190.
  • 7. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851-60. doi: 10.1056/NEJMoa011303.
  • 8. Fernandez-Fernandez B, Ortiz A, Gomez-Guerrero C, Egido J. Therapeutic approaches to diabetic nephropathy—beyond the RAS. Nat Rev Nephrol. 2014;10(6):325. doi: 10.1038/nrneph.2014.74.
  • 9. Gallagher H, Suckling RJ. Diabetic nephropathy: where are we on the journey from pathophysiology to treatment? Diabetes Obes Metab. 2016 Jul;18(7):641-7. doi: 10.1111/dom.12630.
  • 10. Gündüz F, Kuru O, Sentürk UK. Effect of nitric oxide on exercise-induced proteinuria in rats. J Appl Physiol (1985). 2003 Nov;95(5):1867-72. doi: 10.1152/japplphysiol.00599.2003.
  • 11. Roccatello D, Mengozzi G, Ferro M et al. Isosorbide 5 mononitrate administration increases nitric oxide blood levels and reduces proteinuria in IgA glomerulonephritis patients with abnormal urinary endothelin/cyclic GMP ratio. Clin Nephrol. 1995;44(3):163-9.
  • 12. Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007 May;39(2):175-91. doi: 10.3758/bf03193146.
  • 13. Lin J, Knight EL, Hogan ML, Singh AK. A comparison of prediction equations for estimating glomerular filtration rate in adults without kidney disease. J Am Soc Nephrol. 2003 Oct;14(10):2573-80. doi: 10.1097/01.asn.0000088721.98173.4b.
  • 14. Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care. 2005;28(1):164-76. doi: 10.2337/diacare.28.1.164.
  • 15. Akhan O, Ardahanli I. Hypoglycemia in the emergency, is there any effect on endothelial and diastolic functions? Echocardiography. 2021 Mar;38(3):450-459. doi: 10.1111/echo.14988.
  • 16. Kim MK. Treatment of diabetic kidney disease: current and future targets. Korean J Intern Med. 2017 Jul;32(4):622-630. doi: 10.3904/kjim.2016.219.
Toplam 16 adet kaynakça vardır.

Ayrıntılar

Birincil Dil İngilizce
Konular Endokrinoloji, Üroloji
Bölüm Araştırma makalesi
Yazarlar

Recep Demirci 0000-0001-5609-9634

Okan Akyüz 0000-0003-2460-9577

Yayımlanma Tarihi 1 Haziran 2021
Yayımlandığı Sayı Yıl 2021 Cilt: 5 Sayı: 6

Kaynak Göster

APA Demirci, R., & Akyüz, O. (2021). The effect of isosorbide-mononitrate on proteinuria in patients with diabetic nephropathy. Journal of Surgery and Medicine, 5(6), 620-622. https://doi.org/10.28982/josam.807627
AMA Demirci R, Akyüz O. The effect of isosorbide-mononitrate on proteinuria in patients with diabetic nephropathy. J Surg Med. Haziran 2021;5(6):620-622. doi:10.28982/josam.807627
Chicago Demirci, Recep, ve Okan Akyüz. “The Effect of Isosorbide-Mononitrate on Proteinuria in Patients With Diabetic Nephropathy”. Journal of Surgery and Medicine 5, sy. 6 (Haziran 2021): 620-22. https://doi.org/10.28982/josam.807627.
EndNote Demirci R, Akyüz O (01 Haziran 2021) The effect of isosorbide-mononitrate on proteinuria in patients with diabetic nephropathy. Journal of Surgery and Medicine 5 6 620–622.
IEEE R. Demirci ve O. Akyüz, “The effect of isosorbide-mononitrate on proteinuria in patients with diabetic nephropathy”, J Surg Med, c. 5, sy. 6, ss. 620–622, 2021, doi: 10.28982/josam.807627.
ISNAD Demirci, Recep - Akyüz, Okan. “The Effect of Isosorbide-Mononitrate on Proteinuria in Patients With Diabetic Nephropathy”. Journal of Surgery and Medicine 5/6 (Haziran 2021), 620-622. https://doi.org/10.28982/josam.807627.
JAMA Demirci R, Akyüz O. The effect of isosorbide-mononitrate on proteinuria in patients with diabetic nephropathy. J Surg Med. 2021;5:620–622.
MLA Demirci, Recep ve Okan Akyüz. “The Effect of Isosorbide-Mononitrate on Proteinuria in Patients With Diabetic Nephropathy”. Journal of Surgery and Medicine, c. 5, sy. 6, 2021, ss. 620-2, doi:10.28982/josam.807627.
Vancouver Demirci R, Akyüz O. The effect of isosorbide-mononitrate on proteinuria in patients with diabetic nephropathy. J Surg Med. 2021;5(6):620-2.
 Kapak Resmi İndir